Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
3-Dose Hepatitis B Vaccine Offers Full Protection for People with HIV
Phase III clinical trials from the University of Cincinnati have shown seroprotection in 100% of HIV-positive participants after a 3-dose regimen of the HEPLISAV-B vaccine.
Manufacturing & Bioprocessing
AAV Manufacturing Using Osmolality
New Data from the Cell and Gene Therapy Catapult shows improved yield, quality, and process efficiency for AAV manufacturing using osmolality.
Antibody & Protein Engineering
Oxford Global's R&D Key 40 Stories 2022
Download a copy of the R&D Key 40 Stories 2022 eBook today.
Bioanalysis
Mass Spectrometry: Shortening Time Scales and Progressing Towards Automation
Discover the top bioanalysis presentations from Biologics UK 2022.
Drug Discovery & Development
T Cell Enhancers: Conditional Activation for a Safe and Durable Response
Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.
NextGen Therapeutics
Gilead Pay Big Bucks for MacroGenics' Blood-Cancer Targeting Bispecific
Gilead announced a $1.7 billion licence-option deal for MacroGenics’ MGD024 bispecific once Phase I trials conclude.
Immunotherapy (Non-Oncology)
Immunology: from Cancer to COVID
Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19.
Bioanalysis
Turbocharging Potency Assays – Challenges and Opportunities from Multispecific Drug Modalities
The development of multispecific drugs is an inherently complex and challenging process. Barbara Hebeis of AstraZeneca talks us through challenges surrounding the development of appropriate potency assays, and the opportunities the field offers.
Antibody & Protein Engineering
The STING in Immunotherapy’s Tail
Research from the University of North Carolina into STING agonists provides new insights for immunotherapy cancer treatments.
Antibody & Protein Engineering
Eisai’s Alzheimer's Drug Offers New Hope
Eisai’s new drug lecanemab has shown small but significant benefits for people with early Alzheimer’s disease.
Biomarkers & Precision Medicine